Will Chou
Company: Aruvant
Job title: CEO
Seminars:
The Promise for ARU-1801, a Differentiated Lentiviral Vector Gene Therapy for Sickle Cell Disease 3:00 pm
Introduction to Aruvant’s gene therapies for rare diseases Overview of how ARU-1801 is a differentiated investigational gene therapy for individuals living with severe sickle cell disease A review of recent data from Aruvant’s ongoing MOMENTUM study in individuals with sickle cell diseaseRead more
day: Day Two
Joint Q&A 5:00 pm
day: Day Two